ReviewAmerican journal of nephrology2021
Mini Review: Reappraisal of Uric Acid in Chronic Kidney Disease.
Review in American journal of nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Urate-lowering effects of polyphenolic compounds in animal models: systematic review and meta-analysis.PeerJ · 2025Pooled it
- Triangulating Evidence on Serum Uric Acid and Cancer Risk: Consistent Inverse Associations With Lung Cancer.Cancer science · 2026Article
- Association of serum uric acid with cardiovascular-kidney-metabolic syndrome in elderly populations: results from Chinese and US cohorts.Scientific reports · 2026Article
- Multiple Reaction Monitoring (MRM)-Based Targeted Kidney Metabolite Profiling of a Mouse Model of Hyperuricemia.Metabolites · 2026Article
- Article
- A machine-learning model to identify concurrent vascular disease in symptomatic patients with chronic obstructive pulmonary disease.Annals of medicine · 2025Article
- Mendelian Randomization Studies: Opening a New Window in the Study of Metabolic Diseases and Chronic Kidney Disease.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Impact of Uric Acid Levels on Mortality and Cardiovascular Outcomes in Relation to Kidney Function.Journal of clinical medicine · 2024Article
- Emerging Roles of Xanthine Oxidoreductase in Chronic Kidney Disease.Antioxidants (Basel, Switzerland) · 2024Review
- Interpretable machine learning framework to predict gout associated with dietary fiber and triglyceride-glucose index.Nutrition & metabolism · 2024Article
- [Retrospective Analysis of the Effect of Uric Acid on the Prognosis of Immunoglobulin A Nephropathy With Stage 3-4 Chronic Kidney Disease].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2023Article
- Genetic susceptibility to diabetic kidney disease is linked to promoter variants of XOR.Nature metabolism · 2023Article
- Gout and hyperuricaemia: modifiable cardiovascular risk factors?Frontiers in cardiovascular medicine · 2023Review
- Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction.Drugs in context · 2023Review
- Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications.Mayo Clinic proceedings · 2022Review
- Update on Uric Acid and the Kidney.Current rheumatology reports · 2022Review
- Sirtuin deficiency and the adverse effects of fructose and uric acid synthesis.American journal of physiology. Regulatory, integrative and comparative physiology · 2022Review
- An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Hyperuricemia predicts the development of chronic kidney disease (CKD) and metabolic complications, but whether it has a causal role has been controversial. This is especially true given the 2 recently conducted randomized controlled trials that failed to show a benefit of lowering uric acid in type 1 diabetes-associated CKD and subjects with stage 3-4 CKD. While these studies suggest that use of urate-lowering drugs in unselected patients is unlikely to slow the progression of CKD, there are subsets of subjects with CKD where reducing uric acid synthesis may be beneficial. This may be the case in patients with gout, hyperuricemia (especially associated with increased production), and urate crystalluria. Here, we discuss the evidence and propose that future clinical trials targeting these specific subgroups should be performed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.